Monty Pal, MD, Discusses Key RCC Highlights From ASCO GU
By Monty Pal, MD - Last Updated: February 6, 2024Dr. Monty Pal discusses impactful data released at the recent ASCO GU meeting, including thoughts on the CheckMate 9ER study and its findings on treatment outcomes based on site of metastasis, as well as quality of life implications for patients treated with nivolumab/cabozantinib.
Advertisement
Advertisement
Related Posts
Dr. Calais explains the utility of PSMA PET prior to RT for unfavorable intermediate-risk or high-risk prostate cancer.
Dr. Saby George continues with the survival implications and ramifications from the CheckMate 214 long-term data.
Dr. Saby George provides details on CheckMate 67T for the utility of subcutaneous nivolumab for advanced or metastatic ccRCC.
Dr. Powles offers his thoughts on the latest OS data from EV-302 for patient subgroups and immune-related toxicity.
Dr. Powles gives his unique feedback on what to make of KEYNOTE-564 and how aRCC frontline options should be compared.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.